Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07103746 · ClinicalTrials.gov registry record · Phase 2
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
A Phase 2 study of Autoimmune Disorders, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 9
- Study locations
NCT07103746 is a Phase 2 study of Autoimmune Disorders that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 30 participants, below the 523-participant average among 3 other Autoimmune Disorders trials with a reported enrollment target (94% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT07103746, a Phase 2 study of Autoimmune Disorders, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a multi-center, Phase 2 trial of ublituximab as first-line combination therapy in early, active autoantibody positive immune-mediated necrotizing myopathy. The primary objective is to estimate the effect of ublituximab as first add-on combination therapy at 24 weeks compared to placebo in treating early, active autoantibody positive immune-mediated necrotizing myopathy using the validated 2016 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Myositis Response Criteria, as measured by the Total Improvement Score (TIS)
Conditions Studied
Interventions
- DRUG Ublituximab
- DRUG Placebo for Ublituximab
Study Locations (9)
Alabama
- University of Alabama at Birmingham School of Medicine: Division of Clinical Immunology & Rheumatology - Birmingham
California
- University of California, Irvine School of Medicine: Division of Rheumatology - Orange
Georgia
- Emory University School of Medicine: Division of Rheumatology - Atlanta
Illinois
- University of Chicago, Department of Medicine: Rheumatology - Chicago
Maryland
- Johns Hopkins Hospital: Division of Rheumatology - Baltimore
Minnesota
- Mayo Clinic: Division of Rheumatology - Rochester
New York
- Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology - Great Neck
Pennsylvania
- University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-02-26 |
| Est. Completion | 2029-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07103746
The ClinicalTrials.gov registry entry for NCT07103746 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 523-participant average among 3 other Autoimmune Disorders trials with a reported enrollment target (94% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autoimmune Disorders appearing as the primary indexed condition, and to 2 interventions - of which Ublituximab is the first listed.
NCT07103746 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Alabama, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT07103746 about?
NCT07103746 is a clinical study titled "Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy". This is a multi-center, Phase 2 trial of ublituximab as first-line combination therapy in early, active autoantibody positive immune-mediated necrotizing myopathy. The primary objective is to estimate the effect of ublituximab as first add-on combination therapy at 24 weeks compared to placebo in t...
What is the current status of trial NCT07103746?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-02-26. Estimated completion is 2029-08.
What conditions does trial NCT07103746 study?
This clinical trial studies the following conditions: Autoimmune Disorders.
What interventions are being tested in trial NCT07103746?
The interventions under investigation include: Ublituximab (DRUG), Placebo for Ublituximab (DRUG).
Who is sponsoring clinical trial NCT07103746?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07103746 being conducted?
This trial has 9 study locations across Alabama, California, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autoimmune Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.